tbuckley/cabot-search huggingface dataset:
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Authors: H.M. Babiker, I. Brana, D. Mahadevan, T.K. Owonikoko, E. Calvo, D. Rischin, V. Moreno, K.P. Papadopoulos, M. Crittenden, S. Formenti, J. Giralt, P. Garrido Lopez, A. Hervás Morón, K.K. Mohan, M.G. Fury, I. Lowy, E. Stankevich, M. Feng, J. Li, M. Mathias
Journal: Annals of Oncology (2018)
P1.16-33 Occult Lymph Node Metastases in Early Stage NSCLC Patients: Where Do We Stand Now? A Proposal for a Preoperative Risk Model
Authors: G. Cipollone, M. Barone, D. Di Nuzzo, M. Ippoliti, B. Maggi, L. Guetti, P. Camplese, D. Divisi, P. Solli, R. Crisci, F. Mucilli
Journal: Journal of Thoracic Oncology (2018)
P1.04-25 The Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)
Authors: Y. Chae, S. Chang, T. Ko, K. Rhee, M. Cruz, M. Bhave, J. Anker, A. Davis, W. Iams, V. Wang, J. Chuang, L.C. Park
Journal: Journal of Thoracic Oncology (2018)
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Authors: J. Puente, M.J. Mendez Vidal, M.I. Saez, A. Font Pous, I. Duran, D. Castellano, M.J. Juan Fita, C. Santander, J.A. Arranz Arija, A. Sanchez-Hernandez, B. Mellado, T. Alonso, M.A. Gonzalez del Alba Baamonde, P. Maroto, M. Lazaro, E. Esteban, J.G. Cassinello, M.A. Climent Duran
Journal: Annals of Oncology (2018)
MA23.10 Cone-Beam Computed Tomography-Guided Microcoil Localization of Pulmonary Nodules During Video-Assisted Thoracic Surgery
Authors: H. Ujiie, A. Gregor, T. Kinoshita, K. Fujino, C. Lee, Y. Motooka, T. Inage, T. Kato, E. Nguyen, K. Yasufuku
Journal: Journal of Thoracic Oncology (2018)
OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial
Authors: F. Barlesi, J. Vansteenkiste, D. Spigel, H. Ishii, M. Garassino, F. De Marinis, M. Özgüroğlu, A. Szczesna, A. Polychronis, R. Uslu, M. Krzakowski, J. Lee, L. Calabro, O. Frontera, B. Ellers-Lenz, M. Bajars, M. Ruisi, K. Park
Journal: Journal of Thoracic Oncology (2018)
MA03.11 Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas
Authors: A. Guirao, L. Molins, I. Ramon, G. Sunyer, N. Vinolas, R. Marrades, D. Sanchez, J.J. Fibla, J. Hernandez, M. Boada, R. Guzman, A. Libreros, A. Agusti
Journal: Journal of Thoracic Oncology (2018)
PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells
Authors: Chen Liang, Si Shi, Mingyang Liu, Yi Qin, Qingcai Meng, Jie Hua, Shunrong Ji, Yuqing Zhang, Jingxuan Yang, Jin Xu, Quanxing Ni, Min Li, Xianjun Yu
Journal: Cancer Research (2018)

Kras is a decisive oncogene in pancreatic ductal adenocarcinoma (PDAC). PIN1 is a key effector involved in the Kras/ERK axis, synergistically mediating various cellular events. However, the underlying mechanism by which PIN1 promotes the development of PDAC remains unclear. Here we sought to elucidate the effect of PIN1 on redox homeostasis in Kras-driven PDAC. PIN1 was prevalently upregulated in PDAC and predicted the prognosis of the disease, especially Kras-mutant PDAC. Downregulation of PIN1 inhibited PDAC cell growth and promoted apoptosis, partially due to mitochondrial dysfunction. Silencing of PIN1 damaged basal mitochondrial function by significantly increasing intracellular ROS. Furthermore, PIN1 maintained redox balance via synergistic activation of c-Myc and NRF2 to upregulate expression of antioxidant response element driven genes in PDAC cells. This study elucidates a new mechanism by which Kras/ERK/NRF2 promotes tumor growth and identifies PIN1 as a decisive target in therapeutic strategies aimed at disturbing the redox balance in pancreatic cancer. SIGNIFICANCE: This study suggests that antioxidation protects Kras-mutant pancreatic cancer cells from oxidative injury, which may contribute to development of a targeted therapeutic strategy for Kras-driven PDAC by impairing redox homeostasis.
SAT0606 Disease modifying anti rheumatic drugs in the treatment of sapho syndrome: systematic literature analysis
Authors: M. Monet, C. Prati, X. Guillot, M. Sondag, F. Verhoeven, F. Aubin, D. Wendling
Journal: Annals of the Rheumatic Diseases (2018)

Background  SAPHO (Synovitis Acne Pustulosis Hyperostosis Osteitis) Syndrome is a rare, heterogeneous clinical entity with cutaneous and osteoarticular expression. The therapeutic management is not codified and there is no validated evaluation tool for SAPHO syndrome.  Objectives  To perform a systematic analysis of the literature in order to evaluate the effects of DMARDs in SAPHO syndrome.  Methods  Bisphosphonates, conventional and targeted synthetic DMARDs, anti-TNF alpha, and other biologics have been subjected to advanced Pubmed research. Treatment was considered effective when the patient validated the response criteria defined in the study or if at least partial benefit was obtained for a minimum of three months. The different treatments were ranked according to their effectiveness rate in three interest groups and then grouped by therapeutic class to determine an overall response rate. These rates led to the calculation of an efficacy index weighted by the number of patients treated in the subgroup (molecule or therapeutic class) compared to the total number of patients in our study.  Results  Treatment efficacy was evaluable in 284 of the 292 patients analysed. The clinical presentation of cases was reported in 205 patients for osteoarticular involvement, and 193 for cutaneous involvement. The group of treatments that most often induces a therapeutic response (in more than 75% of cases) includes Ibandronate, Etanercept, Anakinra, Infliximab, Pamidronate and Adalimumab. Pamidronate, which represents the largest subpopulation in our study, has the highest weighted index of efficacy. Zoledronic acid, Lefulnomide, Ustekinumab and Methotrexate have less often induced a therapeutic effect (efficacy between 50% and 75%) and Sulfasalazine and Secukinumab have response rates of less than 30%. In total, bisphosphonates and TNF alpha antagonists have efficacy rates of 87.77% and 85% respectively. The weighted index, more than twice as high for bisphosphonates (42.96 versus 17.96), reflects the predominant use of these in SAPHO syndrome, with most often a beneficial effect. Conventional and synthetic targeted DMARDs and other biological treatments are less often effective in our study, with response rates of 47% and 58% respectively. The frequencies of each clinical manifestation were in agreement with the data of the literature. There was no clear clinical profile of a good responder to a particular treatment.  Conclusions  This work made it possible to rank the different DMARDs used in the SAPHO syndrome. Anti TNF alpha and Pamidronate are the treatments that seem to bring the higher benefit.  Disclosure of Interest  None declared
Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury
Authors: Maria Ruart, Laia Chavarria, Genís Campreciós, Nuria Suárez-Herrera, Carla Montironi, Sergi Guixé-Muntet, Jaume Bosch, Scott L. Friedman, Juan Carlos Garcia-Pagán, Virginia Hernández-Gea
Journal: Journal of Hepatology (2018)
OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.
Authors: J. Mazieres, L. Montané, F. Barlesi, B. Coudert, P.J. Souquet, J. Otto, R. Gervais, D. Moro-Sibilot, I. Monnet, E. Brain, O. Huillard, G. Quéré, D. Debieuvre, E. Fabre, M. Jaffro, S. Collot, G. Ferretti, C. Tiffon, C. Mahier - Ait Oukhatar, J. Blay
Journal: Journal of Thoracic Oncology (2018)
Multiple roles of lymphatic vessels in peripheral lymph node development
Authors: Esther Bovay, Amélie Sabine, Borja Prat-Luri, Sudong Kim, Kyungmin Son, Ann-Helen Willrodt, Cecilia Olsson, Cornelia Halin, Friedemann Kiefer, Christer Betsholtz, Noo Li Jeon, Sanjiv A. Luther, Tatiana V. Petrova
Journal: The Journal of Experimental Medicine (2018)

The mammalian lymphatic system consists of strategically located lymph nodes (LNs) embedded into a lymphatic vascular network. Mechanisms underlying development of this highly organized system are not fully understood. Using high-resolution imaging, we show that lymphoid tissue inducer (LTi) cells initially transmigrate from veins at LN development sites using gaps in venous mural coverage. This process is independent of lymphatic vasculature, but lymphatic vessels are indispensable for the transport of LTi cells that egress from blood capillaries elsewhere and serve as an essential LN expansion reservoir. At later stages, lymphatic collecting vessels ensure efficient LTi cell transport and formation of the LN capsule and subcapsular sinus. Perinodal lymphatics also promote local interstitial flow, which cooperates with lymphotoxin-β signaling to amplify stromal CXCL13 production and thereby promote LTi cell retention. Our data unify previous models of LN development by showing that lymphatics intervene at multiple points to assist LN expansion and identify a new role for mechanical forces in LN development.
Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations
Authors: Z. Chen, Y. Zheng, W. Cao, Y. Zhang, S. Cai, X. Shao, J. Huang, W. Ye, Y. Huang, Y. Yin, X. Wang
Journal: Annals of Oncology (2018)
P2.17-18 A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer
Authors: J. Taugner, O. Roengvoraphoj, L. Käsmann, O. Petruknov, K. Gennen, A. Reem, M. Dantes, C. Eze, C. Belka, F. Manapov
Journal: Journal of Thoracic Oncology (2018)
P1.04-03 Suppressive Immune Cell Profiling in Patients with Non-Small Cell Lung Cancer
Authors: J. Koh, K.Y. Lee, B. Kim, M.S. Kim, H.J. Cho, Y.H. Bae, B.M. Ku, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2018)
Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC)
Authors: S. Yaung, L. Xi, C. Woestmann, S. McNamara, B. Hinzmann, S. Froehler, N. Tikoo, C. Ju, A. Balasubramanyam, H.-P. Adams, M. Thomas, F. Lasitschka, M. Meister, M. Schneider, F.J.F. Herth, T. Muley, B. Wehnl, J. Palma, X.M. Ma
Journal: Annals of Oncology (2018)
Abstract 18858: Demographics, Outcomes and Mortality Predictors of PCI versus CABG in Septuagenarians and Older Chronic Total Occlusion Patients: A Nationwide Inpatient Analysis
Authors: Upenkumar Patel, Rupak Desai, Rushik Bhuva, Shobhit Sharma
Journal: Circulation (2017)

Background: There is always been a debate over superiority between Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass Grafting (CABG) for old aged Chronic Total Occlusion (CTO) pat...
Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
Authors: K. Kato, M.A. Shah, P.C. Enzinger, J. Bennouna, L. Shen, A. Adenis, J.-M. Sun, B.C. Cho, M. Ozguroglu, T. Kojima, V. Kostorov, C. Hierro, Y. Zhu, S. Shah, P. Bhagia, T. Doi
Journal: Annals of Oncology (2018)
A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)
Authors: C.J. Hoimes, C. Albany, J. Hoffman-Censits, M.T. Fleming, E. Trabulsi, J. Picus, C. Cary, M.O. Koch, R. Walling, W. Kelly, J.L. Godwin, M. Cooney, P. Fu, A. Nelson, K. Patel, C. Eitman, T. Breen, A. Neal, H. Kaimakliotis
Journal: Annals of Oncology (2018)
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
Authors: J.-L. Pujol, L. Greillier, C. Audigier Valette, D. Moro-Sibilot, L. Uwer, J. Hureaux, L. Thiberville, D. Carmier, J. Madelaine, J. Otto, V. Gounant, P. Merle, P. Mourlanette, O. Molinier, P.A. Renault, J. Mazieres, M. Antoine, A. Langlais, F. Morin, P.-J. Souquet
Journal: Annals of Oncology (2018)
Chromosome-level assembly reveals extensive rearrangement in saker falcon and budgerigar, but not ostrich, genomes
Authors: Rebecca E O’Connor, Marta Farré, Sunitha Joseph, Joana Damas, Lucas Kiazim, Rebecca Jennings, Sophie Bennett, Eden A Slack, Emily Allanson, Denis M Larkin, Darren K Griffin
Journal: Genome biology (2018)

The number of de novo genome sequence assemblies is increasing exponentially; however, relatively few contain one scaffold/contig per chromosome. Such assemblies are essential for studies of genotype-to-phenotype association, gross genomic evolution, and speciation. Inter-species differences can arise from chromosomal changes fixed during evolution, and we previously hypothesized that a higher fraction of elements under negative selection contributed to avian-specific phenotypes and avian genome organization stability. The objective of this study is to generate chromosome-level assemblies of three avian species (saker falcon, budgerigar, and ostrich) previously reported as karyotypically rearranged compared to most birds. We also test the hypothesis that the density of conserved non-coding elements is associated with the positions of evolutionary breakpoint regions.We used reference-assisted chromosome assembly, PCR, and lab-based molecular approaches, to generate chromosome-level assemblies of the three species. We mapped inter- and intrachromosomal changes from the avian ancestor, finding no interchromosomal rearrangements in the ostrich genome, despite it being previously described as chromosomally rearranged. We found that the average density of conserved non-coding elements in evolutionary breakpoint regions is significantly reduced. Fission evolutionary breakpoint regions have the lowest conserved non-coding element density, and intrachromomosomal evolutionary breakpoint regions have the highest.The tools used here can generate inexpensive, efficient chromosome-level assemblies, with > 80% assigned to chromosomes, which is comparable to genomes assembled using high-density physical or genetic mapping. Moreover, conserved non-coding elements are important factors in defining where rearrangements, especially interchromosomal, are fixed during evolution without deleterious effects.
P2.09-11 TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density
Authors: S. Hernandez, B. Angulo, C. Dominguez, A. Caminoa, A. Muriel, M. Alonso, L. Jimenez, R. Peñalver, A. Collazo-Lorduy, B. Jimenez, P. Garrido, L. Paz-Ares, J. De Castro, E. Conde, F. Lopez-Rios
Journal: Journal of Thoracic Oncology (2018)
P2.15-28 Effect of Insurance Types on Tumor Recurrence and Overall Survival in Resectable Non-Small Lung Cancer Patients in Northern Thailand
Authors: A. Tantraworasin, S. Siwachat, E. Taioli, S. Saeteng, N. Lertprasertsuke, J. Euathrongchit, B. Chewaskulyong, S. Kongkarnka, Y. Wannasopha, T. Suksombooncharoen
Journal: Journal of Thoracic Oncology (2018)
Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study
Authors: A. Prat, B. Adamo, J.A. Perez Fidalgo, S. Blanch, N. Martinez, P. Gomez Pardo, A. López González, L. Murillo Juso, K. Amillano, M. Vidal, T. Pascual, L. Pare, J. Canes, P. Galvan, B. Gonzalez Farre, V. Ortega Cebrian, X. Gonzalez, M. Bellet Ezquerra, P. Villagrasa, E.M. Ciruelos
Journal: Annals of Oncology (2018)
Clinical utility of serum type III collagen in patients with pancreatic carcinoma
Authors: I. Chen, N. Willumsen, C. Dehlendorff, A. Johansen, B.V. Vittrup, M. Krüger, P. Pfeiffer, J.K. Bjerregaard, S.E. Bojesen, S.E. Nielsen, N.H. Holländer, M.K. Yilmaz, L.S. Rasmussen, M. Karsdal, J.S. Johansen
Journal: Annals of Oncology (2018)
P1.13-37 Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer
Authors: H. Tran, V. Lam, M. Vasquez, L. Hong, R. Colen, N. Elshafeey, I. Hassan, E. Prado, V. Papadimitrakopoulou, G. Blumenschein, B. Carter, G. Simon, L. Byers, M. Altan, Y. Elamin, R. Lanman, V. Raymond, A. Tsao, D. Gibbons, F. Fossella, J. Zhang, J. Heymach
Journal: Journal of Thoracic Oncology (2018)
P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
Authors: D. Ksienski, E. Wai, M. Lesperance, N. Croteau, L. Fiorino, Z. Poonja, G. Geller, D. Fenton, E. Brooks, D. Glick
Journal: Journal of Thoracic Oncology (2018)
Bariatric surgery is associated with lower risk of acute care use for cardiovascular disease in obese adults
Authors: Yuichi J Shimada, Koichiro Gibo, Yusuke Tsugawa, Tadahiro Goto, Elaine W Yu, Hiroyasu Iso, David F M Brown, Kohei Hasegawa
Journal: Cardiovascular Research (2018)

Studies have suggested relationships between obesity and cardiovascular disease (CVD) morbidity. However, little is known about whether substantial weight reduction affects the risk of CVD-related acute care use in obese patients with CVD. The objective of this study was to determine whether bariatric surgery is associated with decreased risk of CVD-related acute care use. We performed a self-controlled case series study of obese adults with CVD who underwent bariatric surgery, using population-based emergency department (ED), and inpatient samples in California, Florida, and Nebraska from 2005 to 2011. The primary outcome was ED visit or unplanned hospitalization for CVD. We used conditional logistic regression to compare the risk during sequential 12-month periods, using pre-surgery months 13–24 as the reference period. We identified 11 106 obese adults with CVD who underwent bariatric surgery. During the reference period, 20.6% [95% confidence interval (CI), 19.8–21.3%] of patients had an ED visit or unplanned hospitalization for CVD. The risk did not significantly change in the subsequent 12-month pre-surgery period [adjusted odds ratio (aOR) 0.98; 95% CI, 0.93–1.04; P = 0.42]. By contrast, in the first 12-month period after bariatric surgery, the risk significantly decreased (aOR 0.91; 95% CI, 0.86–0.96; P = 0.002). The risk remained reduced in the subsequent 13–24 months post-bariatric surgery (aOR 0.84; 95% CI, 0.79–0.89; P < 0.001). There was no reduction in the risk in separate obese populations that underwent non-bariatric surgery (i.e. cholecystectomy, hysterectomy). By CVD category, the risk of acute care use for coronary artery disease (CAD), heart failure (HF), and hypertension decreased after bariatric surgery, whereas that of dysrhythmia and venous thromboembolism transiently increased (Bonferroni corrected P < 0.05 for all comparisons). Bariatric surgery is associated with a lower risk of overall CVD-related ED visit or unplanned hospitalization. The decline was mainly driven by reduced risk of acute care use for CAD, HF, and hypertension after bariatric surgery.
P3.03-21 CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients
Authors: A. Fung, K. Kopciuk, M. Dean, A. D'Silva, S. Otsuka, A. Klimowicz, D. Hao, D. Morris, G. Bebb
Journal: Journal of Thoracic Oncology (2018)
Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
Authors: D.S. Tan, S.-W. Kim, L.V. Sequist, S. Ponce Aix, E.F. Smit, T. Hida, J.C.-H. Yang, E. Felip, T. Seto, C. Grohe, J. Wolf, J. Ko, E. Marriere, R. Belli, M. Giovannini, D.-W. Kim
Journal: Annals of Oncology (2018)
Translocation of a Stray Cat Infected with Rabies from North Carolina to a Terrestrial Rabies-Free County in Ohio, 2017
Authors: Amber J. Singh, Richard B. Chipman, Sietske de Fijter, Richard Gary, Marilyn G. Haskell, Jordona Kirby, Li Yu, Rene E. Condori, Lillian Orciari, Ryan Wallace
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

On July 24, 2017, the Ohio Department of Health (ODH) was notified of a positive rabies test result from a domestic cat in Summit County, a county considered free from terrestrial rabies. Oral rabies vaccination (ORV) of raccoons, in the form of consumable bait, is conducted each year along the Ohio-Pennsylvania border to prevent the westward expansion of the raccoon rabies virus variant (RVV). In the United States, several distinct rabies virus variants exist; raccoon RVV is enzootic along the eastern parts of the United States (from Florida to Maine), including several counties in northeast Ohio (1). Animal rabies vaccination is protective against all rabies virus variants. The rabid cat (cat A) was located west of the ORV barrier, raising concern that it had acquired the infection from a raccoon and suggesting a possible breach in the ORV barrier (Figure 1). ODH initiated an investigation to identify persons and animals exposed to the rabid cat during its viral shedding period and collaborated with CDC to determine the likely origin of the virus (Figure 2). Public health investigators later discovered that the cat originated in North Carolina. Phylogenetic analysis confirmed that the virus was most similar to the raccoon RVV that circulates in North Carolina (Figure 3); therefore, this ORV breach was likely the result of human-mediated movement of a rabid animal rather than natural expansion of the raccoon rabies virus enzootic area. This report summarizes the investigation and highlights the importance of owner compliance regarding rabies vaccination.
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study
Authors: M. Araz, M. Karaağaç, L. Korkmaz, L. Koral, F. İnci, I. Beypinar, M. Uysal, M. Artac
Journal: Annals of Oncology (2018)
Abstract 16919: Haploinsufficiency of Scn1b Encoding Sodium Channel Beta1 Subunit Alters Cardiac Function
Authors: Alejando Andrade, Kevin Agostinucci, Sharath Khandi, Dong Sun, Leonard Eisenberg, Heather O'Malley, Lori L Isom, Thomas H Hintze, Marcello Rota
Journal: Circulation (2017)

Diastolic dysfunction is typically observed in the elderly population and is reiterated experimentally in aged rodents, together with enhancement of the late Na+ current in cardiomyocytes, a factor...
PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Authors: M.A. Khattak, E.S. Gray, A. Reid, M. Periera, A. McEvoy, C. Aya-Bonilla, T. Meniawy, A. Didan, M. Millward, M. Ziman
Journal: Annals of Oncology (2018)
Abstract 20204: Syntax-Score II Based Assessment of Percutaneous Coronary Intervention for Patients With Chronic Total Occlusion
Authors: Masanori Shiba, Megumi Minakawa, Masato Nakamura
Journal: Circulation (2017)

Introduction: SYNTAX-score II as newer tool to select revascularization strategy between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) may be useful to assess ...
Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
Authors: B.I. Rini, M. Huseni, M.B. Atkins, D.F. McDermott, T.B. Powles, B. Escudier, R. Banchereau, L.-F. Liu, N. Leng, J. Fan, J. Doss, S. Nalle, S. Carroll, S. Li, C. Schiff, M. Green, R.J. Motzer
Journal: Annals of Oncology (2018)
Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
Authors: B.C. Cho, R. Obermannova, S.V. Orlov, U. Batra, S.L. Geater, M. McKeage, C.-T. Yang, P.E. Postmus, G. de Castro, S.-W. Kim, P. De Marchi, G.B. Kanakasetty, V. Sriuranpong, P.J. Voon, Y.Y. Lau, F. Kiertsman, V.Q. Passos, Z. Chen, R. Dziadziuszko
Journal: Annals of Oncology (2018)